Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
SLRN.US
id: 877
Acelyrin (SLRN) Clinical Trial Case
C.D. California
Court2:23-cv-09672
Case number05/04/2023
Class period Start09/11/2023
Class period End01/15/2024
Lead Plaintiff motion deadline- Acelyrin allegedly exaggerated one of its main product effectiveness.
- On September 13, 2023, the truth came out, leading to a 16% $SLRN fall.
Acelyrin went public in May, 2023, selling 30 million shares at $18.00 each.
In September, Acelyrin revealed disappointing results for izokibep (one of its main drugs) in a clinical trial.
This news caused $SLRN fall by 16% and $203M loss of market cap, damaging shareholders.
Given all this information, investors have reason to suspect that Acelyrin misled about izokibep's success, leading to an overestimation of its business prospects after going public.
Case Status
Motion to dismiss
Alleged Offence
Mismanagement,
Misleading Statements,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
09/13/2023
Filing date
11/15/2023
Lead Plaintiff Deadline
01/15/2024
Judge
Maria A Audero